January 2026

The Neuroendocrine Tumor Research Foundation (NETRF) has announced its latest round of neuroendocrine cancer research grant recipients. The thirteen investigators receiving awards are pursuing innovative, promising research that has the potential to improve the lives of those living with neuroendocrine cancer. Funding for these thirteen grants totals $2.8 million, bringing NETRF’s all-time investment in research to almost $43 million. Read more. 

Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade forms of the disease. From radiopharmaceuticals and drug conjugates to viral therapies and T-cell engagers, these studies reflect the evolving science behind how we detect, target, and treat neuroendocrine cancer.

In this clinical trial roundup, NETRF highlights four studies that are testing new mechanisms, expanding the reach of existing therapies, or taking the first step into human trials. Read more.

Surveys help bring the patient experience to light. They’ve been critical for raising awareness, validating what patients go through, and showing how disruptive delays can be.

A newly published analysis offers a complementary perspective. In simple terms, it asks: across an entire health system, what does the path to diagnosis look like for people who were ultimately diagnosed with neuroendocrine cancer?Read more.

An exciting development in neuroendocrine cancer treatment in recent years has been the introduction of tarlatamab, a new immunotherapy. Yet, doctors have not had a reliable way to predict who will respond to the drug before starting treatment. A new study offers a promising solution that relies on a simple blood draw. Read more.

The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to share an important leadership transition within our Board of Scientific Advisors (BOSA), a group of distinguished experts who help guide NETRF’s research strategy, strengthen our grantmaking, and keep scientific rigor and patient impact at the center of everything we do. Read more.

NETRF is pleased to announce that Josh Mailman has been elected President of NETRF’s Board of Directors. A member of the NETRF Board since 2016, Josh is an internationally recognized neuroendocrine cancer patient advocate whose leadership and passion have strengthened NETRF’s mission to drive research and improve outcomes for patients.

Joining Josh as NETRF officers are Suzanne Ludlow, Vice President; Valorie Seyfert, Treasurer; and Carrie Camino, Clerk. Together, this leadership team brings deep commitment and experience to guide NETRF’s work in the years ahead.

The NETRF Board, staff, and scientific advisors extend their sincere gratitude to outgoing President Todd Gilman for his exceptional leadership over the past four years. We also thank outgoing Vice President Julie Mebane for her tremendous dedication and support. Under their guidance, NETRF made remarkable progress advancing research and serving the neuroendocrine cancer community. Both Todd and Julie will continue to serve on the Board, and we are grateful for their continued engagement and service.

Jamie Metzl is a writer and technology/healthcare futurist who regularly speaks to the medical industry on the future of healthcare. When Jamie’s father, Kurt Metzl, was diagnosed with pancreatic neuroendocrine cancer in 2022 at the age of 87, Jamie helped his father navigate major healthcare decisions and gained practical knowledge he is eager to share with cancer caregivers.
Read more.

As the neuroendocrine cancer field moves into a new year, the focus isn’t on looking back—it’s on what’s coming next. This episode of NETWise explores the future of neuroendocrine cancer research and what it means for patients, caregivers, and clinicians.

Recorded in connection with the 2025 Margie and Robert E. Petersen Neuroendocrine Tumor Research Symposium, the conversation brings together researchers, physicians, patient advocates, and NETRF leaders to unpack the momentum shaping the next era of care—from emerging therapies and precision medicine to the growing role of patient education and thrivership.

This isn’t a distant vision of what might be possible, but the work already underway and the direction the field is already headed.

Neuroendocrine cancer patients and caregivers are at the heart of everything NETRF does. Each year, we ask what you want to learn at KNOW YOUR NETs, and your input has shaped our most impactful and successful patient conferences to date.

As we plan for the next KNOW YOUR NETs conference, we want to build on that success with your guidance. As someone living with neuroendocrine cancer or caring for someone who is, your expert feedback will directly inform the content and format of our next conference.

Please take five minutes to complete this brief survey and help us create a KNOW YOUR NETs experience that truly meets your needs.

In this Thrivership series, we explore what it means to find peace in uncertainty. Peace doesn’t always come with clarity or answers. Often, it arrives quietly—one step, one choice, one breath at a time. For many living with illness or ongoing uncertainty, the unknown isn’t occasional; it’s part of daily life. Thrivership asks a different question: not "How do we eliminate uncertainty?" but "How do we move forward with intention anyway?"

NETRF CEO Elyse Gellerman recently joined a panel of physicians to discuss patient advocacy, in an episode of NETCast, a podcast produced by the North American Neuroendocrine Tumor Society (NANETS). The discussion included the importance of advocacy to drive meaningful changes in awareness, treatment, and research. Listen and find out how you can be an effective advocate for yourself and the community.

In November 2025, Drew Greenberg marked his Bar Mitzvah in a way that moved everyone who heard his story. At just 13 years old, Drew chose to honor his father, Dr. David Ross Greenberg, by turning this milestone into a mitzvah project supporting neuroendocrine cancer research.

David died from neuroendocrine cancer in May 2025, only months before Drew’s Bar Mitzvah. He was a brilliant engineer, a lifelong learner, and a deeply compassionate person who was known for his warmth, humor, and generosity. After a distinguished career in electrical engineering, David devoted himself to his family and his community, volunteering his time and sharing his

knowledge freely with others. Above all, he was a devoted and loving father who took immense pride in his son. Read more.

The neuroendocrine cancer community is mourning the loss of Dr. Sue O’Dorisio, who passed away in December. A true pioneer in the field, Dr. O’Dorisio, along with her husband Tom, cared for thousands of patients and mentored countless students and physicians at the University of Iowa Carver College of Medicine.

Dr. O’Dorisio served as Professor of Pediatrics and specialized in neuroendocrine tumors. She was a driving force behind the creation of a multidisciplinary neuroendocrine tumor center at the Holden Comprehensive Cancer Center at the University of Iowa.

In 2015, the program received a Specialized Programs of Research Excellence (SPORE) grant to advance the prevention, detection, diagnosis, and treatment of NETs, and in 2019 it was awarded an ENETS Center of Excellence designation.

Dr. O’Dorisio’s research in beta- and alpha-emitting radionuclides helped open new pathways for imaging and treatment. Her contributions have been recognized worldwide and included many honors, such as the University of Iowa Carver College of Medicine Distinguished Mentor Award and the North American Neuroendocrine Tumor Society Lifetime Achievement Award.

NETRF extends its heartfelt condolences to her family and joins the neuroendocrine cancer community in honoring Dr. O’Dorisio’s lasting impact on the field.

NET Research Foundation
100 Hancock Street,
Third floor
Quincy, MA 02171
(617) 946-1780 info@netrf.org

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancer. NETRF is the largest global funder of neuroendocrine research and a preeminent resource for expert patient education and support.



NETRF is a 501(c)(3) organization. All donations are tax-deductible to the extent allowed by law.